Dr Christopher Brereton

Dr Christopher Brereton’s research focus is on improving access for patients with chronic respiratory diseases to clinical research trials; increasing our understanding of the mechanisms of pulmonary fibrosis and bridging the gap between translational science and clinical practice.

Publications:

• Brereton CJ, Yao L, Davies ER, Zhou Y, Vukmirovic M, Bell JA, Wang S, Ridley RA, Dean LSN, Andriotis OG, Conforti F, Brewitz L, Mohammed S, Wallis T, Tavassoli A, Ewing RM, Alzetani A, Marshall BG, Fletcher SV, Thurner PJ, Fabre A, Kaminski N, Richeldi L, Bhaskar A, Schofield CJ, Loxham M, Davies DE, Wang Y, Jones MG. Pseudohypoxic HIF pathway activation dysregulates collagen structure-function in human lung fibrosis. Elife. 2022 Feb 21;11:e69348.
• Wallis T, Gudmundsson E, Pontoppidan K, Mogulkoc N, Savas R, Unat O, Vedwan K, Battison S, Thompson F, Brereton CJ, Marshall BG, Fletcher SV, Richeldi L, Jacob J, Jones MG. Temporal progression of mediastinal lymphadenopathy in idiopathic pulmonary fibrosis. ERJ. Accepted for publication Jan 2022.
• Gudmundsson E, Zhao A, Mogulkoc N, Stewart I, Jones MG, Van Moorsel CHM, Savas R, Brereton CJ, Van Es HW, Unat O, Pontoppidan K, Van Beek F, Veltkamp M, Gholipour B, Nair A, Wells AU, Janes SM, Alexander DC, Jacob J. Pleuroparenchymal fibroelastosis in idiopathic pulmonary fibrosis: Survival analysis using visual and computer-based computed tomography assessment. EClinicalMedicine. 2021 Jul 13;38:101009
• Zhao A, Gudmundsson E, Mogulkoc N, Jones MG, van Moorsel C, Corte TJ, Romei C, Savas R, Brereton CJ, van Es HW, Jo H, De Liperi A, Unat O, Pontoppidan K, van Beek F, Veltkamp M, Hopkins P, Moodley Y, Taliani A, Tavanti L, Gholipour B, Nair A, Janes S, Stewart I, Barber D, Alexander DC, Wells AU, Jacob J. Mortality in combined pulmonary fibrosis and emphysema patients is determined by the sum of pulmonary fibrosis and emphysema. ERJ Open Res. 2021 Aug 23;7(3):00316-2021
• Johnson PB, Karvounis A, Singh HJ, Brereton CJ, Bourdakos KN, Lunn K, Roberts JJW, Davies DE, Muskens OL, Jones MG, Mahajan S. Superresolved polarization-enhanced second-harmonic generation for direct imaging of nanoscale changes in collagen architecture. Optica. 2021 May 13;8(5):674-685
• James DS, Brereton CJ, Davies DE, Jones MG, Campagnola PJ. Examining lysyl oxidase-like modulation of collagen architecture in 3D spheroid models of idiopathic pulmonary fibrosis via second-harmonic generation microscopy. J Biomed Opt. 2021 Jun;26(6):066501
• Brereton CJ, Jo HE. Acute exacerbations of idiopathic pulmonary fibrosis and the role of corticosteroids. Breathe (Sheff). 2020 Sep;16(3):200086.
• Conforti F, Ridley R, Brereton C, Alzetani A, Johnson B, Marshall BG, Fletcher SV, Ottensmeier CH, Richeldi L, Skipp P, Wang Y, Jones MG, Davies DE. Paracrine SPARC signaling dysregulates alveolar epithelial barrier integrity and function in lung fibrosis. Cell Death Discov. 2020 Jun 30;6(1):54
• Brereton CJ, Wallis T, Casey M, Fox L, Pontopiddan K, Laws D, Graves J, Titmuss V, Kearney S, Evans S, Grove A, Hamid S, Richeldi L, O’Reilly KMA, Fletcher SV, Jones MG. Time taken from primary care referral to a specialist centre diagnosis of idiopathic pulmonary fibrosis: an opportunity to improve patient outcomes? ERJ Open Res. 2020 Jul 20;6(2):00120-2020
• Jacob J, Aksman L, Mogulkoc N, Proctor AJ, Gholipour B, Cross G, Barnett J, Brereton CJ, Jones MG, van Moorsel CH, van EsW, van Beek F, Veltkamp M, Desai SR, Judge E, Burd T, Kokosi M, Savas R, Bayraktaroglu S, Altmann A, Wells AU. Serial CT analysis in idiopathic pulmonary fibrosis: comparison of visual features that determine patient outcome. Thorax, Apr 2020, thoraxjnl-2019-213865.
• Hill, C., Li, J., Liu, D., Conforti, F., Brereton CJ., Yao, L., Zhou, Y., Alzetani, A., Chee, S. J., Marshall, B. G., Fletcher, S. V., Hancock, D., Ottensmeier, C. H., Steele, A. J., Downward, J., Richeldi, L., Lu, X., Davies, D. E., Jones, M. G., & Wang, Y. Autophagy inhibition-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis. Cell death & disease, Aug 2019, 10(8), 591.
• Fletcher SV, Jones MG, Renzoni EA, Parfrey H, Hoyles RK, Spinks K, Kokosi M, Kwok A, Warburton C, Titmuss V, Thillai M, Simler N, Maher TM, Brereton CJ, Chua F, Wells AU, Richeldi L, Spencer LG. Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice. ERJ Open Res. 2018 Oct 19;4(4). pii: 00049-2018.
• Jones MG, Andriotis OG, Roberts JJ, Lunn K, Tear VJ, Cao L, Ask K, Smart DE, Bonfanti A, Johnson P, Alzetani A, Conforti F, Doherty R, Lai CY, Johnson B, Bourdakos KN, Fletcher SV, Marshall BG, Jogai S, Brereton CJ, Chee SJ, Ottensmeier CH, Sime P, Gauldie J, Kolb M, Mahajan S, Fabre A, Bhaskar A, Jarolimek W, Richeldi L, O’Reilly KM, Monk PD, Thurner PJ, Davies DE. Nanoscale dysregulation of collagen structure-function disrupts mechano-homeostasis and mediates pulmonary fibrosis. Elife. 2018 Jul 3;7. pii: e36354
• Brereton CJ, Lennon D, Browning S, Dunn E, Ferguson JK, Davis JS. Is gentamicin safe and effective for severe community-acquired pneumonia? An 8-year retrospective cohort study. Int J Antimicrob Agents. 2018 Jun;51(6):862-866